An Open-label Pilot Study to Evaluate the Safety, Tolerability,Pharmacokinetics, Exploratory Efficacy and Pharmacodynamics of Oral Pazopanib Administered for 28 Days to Neovascular Age-relatedmacular Degeneration Patients
Latest Information Update: 25 Aug 2023
At a glance
- Drugs Pazopanib (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 29 Sep 2014 New trial record